VIVIT Pharma

VIVIT Pharma is a clinical-stage biotechnology company dedicated to developing a new class of highly specific immunosuppressants for the treatment of autoimmune and inflammatory diseases. The company's proprietary technology targets the calcineurin-NFAT signaling pathway, a master regulator of the immune response. By specifically inhibiting the interaction between calcineurin and the transcription factor NFAT, VIVIT Pharma aims to achieve potent immunosuppression without the broad toxicity associated with conventional calcineurin inhibitors like cyclosporine A. The lead candidate, VP-001, is a peptide-based therapeutic currently being developed for dermatological indications, including atopic dermatitis. Headquartered in Berlin, Germany, the company was founded on pioneering research from the La Jolla Institute for Immunology.